SURVYR

GRAL

GRAIL, Inc.
$157.88
+$7.27 (4.83%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-51%-14%+22%+59%+96%Oct 2025Oct 2026Apr 202652w high $166.4752w low $41.50
GRALSPY
Wall St. Highest PT $180.00 (+14.0%) Wall St. Avg PT $132.56 (-16.0%)
$43$79$114$150$185POC $72Hi $180Avg $133
Underwater Drawdown %Max DD -62.9%Current 0.0%
0.0%-62.9%
Relative Strength vs SPY+71.8% vs SPYOutperforming
+83%0%-83%
1W
+$25.28 (19.06%)
1M
+$25.25 (19.04%)
3M
+$94.44 (148.87%)
6M
+$108.19 (217.73%)
YTD
+$72.29 (84.46%)
1Y
+$71.52 (82.82%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
9 analysts · mean score 2.00
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$157.88
Average target$132.56
−$25.32 (−16.0%) downsideaverage target vs current price
CurrentAverageMedian
Low$74.00
Median$132.56
High$180.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-13 · Morgan Stanley reiterated Equal-Weight on GRAL
Reiterated
2026-10-13 · TD Cowen reiterated Buy on GRAL
Reiterated
2026-10-02 · UBS reiterated Buy on GRAL
Reiterated
2026-10-01 · Guggenheim reiterated Buy on GRAL
Reiterated
2026-09-28 · Canaccord Genuity reiterated Buy on GRAL
Reiterated
2026-09-25 · Mizuho reiterated Neutral on GRAL
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$5.9B
P/E (next 12 months, estimated)-16.1
52-week range$41.50 – $166.47
Revenue growth (latest quarter vs a year ago)+25.7%
Dividend yieldNo dividend
Analyst consensusBuy (9)
Average analyst price target$132.56 (-16%)

What they do

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.

Healthcare · Diagnostics & Research
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for GRAL yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

GRAL earningsNext report in 6 days
Next report · quarter Sep 2026
Wed Nov 4, 2026After the close
EPS consensus-$1.90 range -$2.85–-$1.49
Revenue consensus$44.1M 10 analysts
Last 4 quarters · EPS vs estimate
Aug 5, 2026-$1.34est -$1.99+33.0%Above estimates
May 5, 2026-$1.37est -$1.96+30.1%Above estimates
Feb 19, 2026-$2.44est -$2.53+3.6%Above estimates
Nov 12, 2025-$2.46est -$3.26+24.7%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-24 03:02:16 ET
24-1125-0225-0525-0825-1126-0226-0526-08-6.430.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$44.7M+25.7%
2026-03-31$40.8M–
2025-12-31$43.6M–
2025-09-30$36.2M–
2025-06-30$35.5M–

News & catalysts

More news
GRAIL to Present at the UBS Global Healthcare Conference
PR Newswire · Oct 27
IBD Stock Of The Day, Natera, Hovering Near Buy Point
Investor's Business Daily · Oct 22
Rating changes
Reiterated
2026-10-13 · Morgan Stanley reiterated Equal-Weight on GRAL
Reiterated
2026-10-13 · TD Cowen reiterated Buy on GRAL
Reiterated
2026-10-02 · UBS reiterated Buy on GRAL
Reiterated
2026-10-01 · Guggenheim reiterated Buy on GRAL
Reiterated
2026-09-28 · Canaccord Genuity reiterated Buy on GRAL
Reiterated
2026-09-25 · Mizuho reiterated Neutral on GRAL

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Ofman Joshua J.
Director, Chief Executive Officer · 2026-10-15
Sell
$293.4K
Ofman Joshua J.
Director, Chief Executive Officer · 2026-10-15
Sell
$830.5K
Ofman Joshua J.
Director, Chief Executive Officer · 2026-10-15
Sell
$964.9K
Ofman Joshua J.
Director, Chief Executive Officer · 2026-10-15
Sell
$460.5K
Ofman Joshua J.
Director, Chief Executive Officer · 2026-10-15
Sell
$134.4K
Ofman Joshua J.
Director, Chief Executive Officer · 2026-10-15
Sell
$53.2K
Freidin Aaron
Chief Financial Officer · 2026-10-05
Sell
$3.5M
Partridge Andrew John
Chief Growth Officer · 2026-10-05
Sell
$1.2M
Ofman Joshua J.
Director, Chief Executive Officer · 2026-09-21
Sell
$1.1M
Ofman Joshua J.
Director, Chief Executive Officer · 2026-09-21
Sell
$211.4K
Ofman Joshua J.
Director, Chief Executive Officer · 2026-09-21
Sell
$42.0K
Ofman Joshua J.
Director, Chief Executive Officer · 2026-09-21
Sell
$137.0K

Stats refreshed 2026-10-24 03:02:16 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026